Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 6 years
- Director since
- 2023
6 years of board service in total across 4 boards, counting each seat separately. Longest: Adicet Bio Inc., 3 years.
Adicet Bio Inc.
Director
Upstream Bio Inc.
Director
Braveheart Bio Inc.
Director
ADARx Pharmaceuticals Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 28, 2026 | ADARx Pharmaceuticals Inc. | Derivative conversion | +7,127,019 | — | — |
| Sep 28, 2026 | ADARx Pharmaceuticals Inc. | Derivative conversion | +1,333,975 | — | — |
| Sep 28, 2026 | ADARx Pharmaceuticals Inc. | Derivative conversion | +513,067 | — | — |
| Sep 28, 2026 | ADARx Pharmaceuticals Inc. | Derivative conversion | +256,448 | — | — |
| Sep 28, 2026 | ADARx Pharmaceuticals Inc. | Open-market purchase | +61,516 | $17.00 | $1,045,772 |
| Aug 7, 2026 | Braveheart Bio Inc. | Derivative conversion | +9,132,420 | — | — |
| Aug 7, 2026 | Braveheart Bio Inc. | Open-market purchase | +1,666,667 | $18.00 | $30,000,006 |
| Aug 7, 2026 | Braveheart Bio Inc. | Open-market purchase | +273,333 | $18.00 | $4,919,994 |
| Oct 15, 2024 | Upstream Bio Inc. | Derivative conversion | +721,956 | — | — |
| Oct 15, 2024 | Upstream Bio Inc. | Open-market purchase | +165,000 | $17.00 | $2,805,000 |
| Oct 15, 2024 | Upstream Bio Inc. | Derivative conversion | +2,887,833 | — | — |
| Oct 15, 2024 | Upstream Bio Inc. | Open-market purchase | +660,000 | $17.00 | $11,220,000 |
Questions about Erez Chimovits
What boards is Erez Chimovits on?
Erez Chimovits sits on the boards of ADARx Pharmaceuticals Inc., Adicet Bio Inc., Braveheart Bio Inc. and Upstream Bio Inc.
How long has Erez Chimovits served on boards?
Our records show at least 6 years of board service across 4 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.